4 reports of this reaction
1.8% of all DEXTROMETHORPHAN HBR AND GUAIFENESIN reports
#17 most reported adverse reaction
NASOPHARYNGITIS is the #17 most commonly reported adverse reaction for DEXTROMETHORPHAN HBR AND GUAIFENESIN, manufactured by Cardinal Health 110, LLC. DBA Leader. There are 4 FDA adverse event reports linking DEXTROMETHORPHAN HBR AND GUAIFENESIN to NASOPHARYNGITIS. This represents approximately 1.8% of all 224 adverse event reports for this drug.
Patients taking DEXTROMETHORPHAN HBR AND GUAIFENESIN who experience nasopharyngitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASOPHARYNGITIS is a less commonly reported adverse event for DEXTROMETHORPHAN HBR AND GUAIFENESIN, but still significant enough to appear in the safety profile.
In addition to nasopharyngitis, the following adverse reactions have been reported for DEXTROMETHORPHAN HBR AND GUAIFENESIN:
The following drugs have also been linked to nasopharyngitis in FDA adverse event reports:
NASOPHARYNGITIS has been reported as an adverse event in 4 FDA reports for DEXTROMETHORPHAN HBR AND GUAIFENESIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASOPHARYNGITIS accounts for approximately 1.8% of all adverse event reports for DEXTROMETHORPHAN HBR AND GUAIFENESIN, making it a notable side effect.
If you experience nasopharyngitis while taking DEXTROMETHORPHAN HBR AND GUAIFENESIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.